Apolipoprotein AIV

Athens Research

Apolipoprotein AIV

9

Cardiovascular Research, Diabetes Research, In Vitro Diagnostic

Research Use Only

≥85% by SDS-PAGE ; immunoreactive by Western Blot to antisera to human apolipoprotein A4

Apolipoprotein A-IV

Apolipoprotein A-IV (ApoA-IV), a glycoprotein synthesized predominantly in the small intestine during fat absorption, is a structural component of HDL and chylomicrons. Its four-helix bundle architecture facilitates lipid emulsification and interaction with apolipoprotein B (apoB) to promote chylomicron assembly and secretion. Postprandially, ApoA-IV dissociates from chylomicrons into the lipoprotein-free plasma fraction, where it activates lecithin-cholesterol acyltransferase (LCAT) and enhances lipoprotein lipase (LPL) activity via apoC-II, critical for triglyceride-rich lipoprotein catabolism. ApoA-IV exhibits protective roles against cardiovascular disease (CVD) by inhibiting vascular inflammation through NF-kappaB suppression and upregulating DHCR24, an anti-inflammatory enzyme. Genetic variants like APOA4 S347 correlate with elevated coronary heart disease (CHD) risk and reduced plasma ApoA-IV levels. In metabolic regulation, ApoA-IV improves insulin sensitivity by stimulating GLUT4 translocation in adipocytes via PI3K-Akt pathways and enhances glucose-stimulated insulin secretion, with deficiencies linked to glucose intolerance. Chronic high-fat diets blunt its satiety signaling, contributing to obesity, while Roux-en-Y gastric bypass increases ApoA-IV, correlating with weight loss and improved glucose control56. Clinically, ApoA-IV serves as a biomarker for CHD risk and diabetes progression. Therapeutic strategies targeting its anti-inflammatory, insulinotropic, and lipid-modulating properties show promise for metabolic and cardiovascular disorders.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

-80C

41116100